Summary & Overview
HCPCS J0285: Injection, Amphotericin B, 50 mg
HCPCS Level II code J0285 designates a 50 mg unit of injectable amphotericin B, an IV antifungal used for severe systemic fungal infections. Nationally, accurate coding of high-cost, hospital-administered drugs like amphotericin B matters for clinical documentation, claims processing, and payer adjudication because it affects reimbursement, inventory tracking, and care coordination for critically ill patients.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a clear description of the code and its clinical context, guidance on typical sites of service where the drug is administered, and an outline of the payer landscape covered. The publication also summarizes common modifier usage and related billing considerations where available, and highlights benchmarking and policy topics relevant to hospital-administered antifungal drugs.
This analysis is written for a national audience and focuses on coding, clinical context, and payer coverage patterns. Data not available in the input is noted where applicable, and the content avoids state-specific guidance.
Billing Code Overview
HCPCS Level II code J0285 represents Injection, amphotericin B, 50 mg. This code describes the drug formulation and unit of service for amphotericin B supplied for parenteral administration.
-
Service type: Injectable antifungal medication
-
Typical site of service: Hospital inpatient, hospital outpatient, or other acute care settings where intravenous antifungal therapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with a serious systemic fungal infection (for example, invasive candidiasis, cryptococcal meningitis, or severe systemic aspergillosis) who requires parenteral antifungal therapy. The patient presents to an inpatient hospital unit, intensive care unit, or infusion center after diagnosis is established by culture, histopathology, or clinical criteria indicating a life‑threatening fungal infection or when an azole therapy is contraindicated. Amphotericin B is prepared by pharmacy as a preservative‑free IV admixture in compatible fluid and is administered via a central venous catheter or peripheral IV under monitoring for infusion‑related reactions, nephrotoxicity, electrolyte disturbances, and hemodynamic changes. Typical workflow steps: medication order entry and weight‑based dose calculation, pharmacy compounding and labeling, verification of infusion pump settings, baseline laboratory evaluation (renal function, electrolytes), administration with premedication as indicated (e.g., acetaminophen, diphenhydramine), continuous nursing monitoring during infusion, and follow‑up labs to assess toxicity and therapeutic response. The usual site of service is inpatient hospital (including ICU), hospital outpatient infusion center, or specialty ambulatory infusion clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies and billing requires code only |